Abstract
Vitamin D deficiency is common in critically ill patients and has been associated with adverse outcomes. Although many interesting observational studies have been published, only four small randomized controlled trials have been conducted in this vulnerable population. Endpoints included bone turnover, inflammatory markers and safety/efficacy issues. However, all of these trials were underpowered to detect clinically relevant endpoints due to their small sample size. Therefore, future studies focusing on morbidity and mortality endpoints are necessary in order to clarify whether vitamin D deficiency is only a surrogate marker for disease severity or whether treatment with sufficiently large doses of vitamin D may improve patient outcome in an intensive care setting.
Keywords: Bone turnover, cholecalciferol, critical illness, critically ill patients, inflammatory markers, intervention trials, vitamin D deficiency.
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Safety
Current Drug Targets
Current Medicinal Chemistry
Current Pharmaceutical Biotechnology
Central Nervous System Agents in Medicinal Chemistry
Letters in Drug Design & Discovery
Current Drug Discovery Technologies
Recent Advances in Anti-Infective Drug Discovery
Related Books
test ebook
Computer-Aided Drug Discovery Methods: A Brief Introduction
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Frontiers in Drug Design and Discovery
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part II
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part I
Frontiers in Cardiovascular Drug Discovery
Frontiers in Drug Design and Discovery
Frontiers in Anti-Cancer Drug Discovery
Frontiers in Drug Design and Discovery
23